Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.38 |
| ▸ | HTR2B | P41595 | 4/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30468374 | 1.00 | HTR2C (0.38) | HTR2CHTR2BHTR2AALOX5APFEN1 | |
| SCHEMBL22391549 | 0.79 | RIPK1 (0.48) | HTR2CHTR2BHTR2AALOX5APFEN1 | |
| SCHEMBL24180121 | 0.79 | ALOX5AP (0.34) | ALOX5APFEN1 | |
| SCHEMBL29786449 | 0.77 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL20472458 | 0.77 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL24018822 | 0.77 | HTR2C (0.45) | HTR2CHTR2BHTR2A | |
| SCHEMBL22371226 | 0.77 | MAOB (0.40) | HTR2CHTR2BHTR2AALOX5APFEN1 | |
| SCHEMBL30468385 | 0.77 | MAOB (0.40) | HTR2CHTR2BHTR2AALOX5APFEN1 | |
| SCHEMBL24180091 | 0.72 | FEN1 (0.41) | HTR2CHTR2BHTR2AALOX5APFEN1 | |
| SCHEMBL24180249 | 0.72 | FEN1 (0.41) | ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440913-B2 | Aminoimidazopyridazines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3704118-B1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-3704118-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440913-B2 | Aminoimidazopyridazines as kinase inhibitors | RIPK1, RIPK4, RIPK3 | HTR2C 3194/4885HTR2B 3339/4885HTR2A 2621/4885 |
| US-20200277296-A1 | AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS | RIPK1, RIPK4, RIPK3 | HTR2C 3194/4885HTR2B 3339/4885HTR2A 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.